China: ICH M11 Electronic Structured Clinical Protocol Guidelines Open for Public Consultation

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released draft implementation recommendations and Chinese translations of the ICH M11 guideline and associated documents for public consultation. The initiative supports the adoption of electronically structured and harmonized clinical protocols in China and aligns local clinical development practices with international standards.

Key highlights:

• Public comments are invited until July 12, 2026, through the designated CDE consultation process
• Draft implementation recommendations and Chinese translations have been issued for ICH M11 and related technical documents
• The guideline establishes a standardized electronic clinical trial protocol format to improve protocol development, review, exchange, and regulatory assessment
• Applicable clinical trials initiated six months after implementation will be expected to comply with the new requirements
• The framework includes harmonized guideline principles, technical specifications, and protocol templates supporting structured data exchange
• Technical specifications define standardized data elements, attributes, business rules, and interoperability requirements for protocol submissions
• The protocol template provides consistent requirements for title pages, trial design, study population, interventions, safety reporting, statistical considerations, and amendment management
• The initiative supports greater protocol consistency, improved regulatory efficiency, enhanced data reuse, and alignment with global ICH standards

This update represents a significant step toward modernization of clinical trial documentation in China and strengthens regulatory convergence with international clinical development standards.